Sleuth
Intel Hub · GLP-1 and Metabolic · Q3 2026
Sleuth Intelligence community

GLP-1 and metabolic, Q3 2026: Novo and Lilly still own the market, so challengers now compete on route, quality of weight loss and durability, often with assets sourced from China

The full analysis behind our Q3 GLP-1 and Metabolic Intel Hub, with the data under every slide, as of August 2026. Click any chart, cell or card to see what sits behind it.

The Excel behind this report is free for Sleuth Intelligence Community members. Get the Excel

How big is the GLP-1 pipeline, and who is building it?

Active GLP-1 programs, each counted once at its highest phase, as of August 2026. Origin is the developer's headquarters.

Origin
China vs U.S. pipeline by phase
Active programs by developer headquarters
Pipeline by route of administration
Share of programs with a stated route

Who earns the GLP-1 dollars, and by which route?

Disclosed brand net sales for Novo Nordisk and Eli Lilly from company reports. Novo figures are converted from Danish kroner at the period-average rate. The 2026 run-rate doubles first-half sales and reads as a conservative floor.

Period
Eli LillyNovo Nordisk

Novo Nordisk retired the Rybelsus brand for Ozempic Pill in May 2026.

Where are GLP-1s going beyond obesity and type 2 diabetes?

Active GLP-1 and incretin programs by indication outside obesity and type 2 diabetes, grouped into Sleuth clusters and counted by phase. A program pursuing several indications counts in each. Counts are approximate, as in the report. Click a cluster to see its indications.

Who is buying GLP-1 assets, and what are they paying?

GLP-1 and key-mechanism business development deals (licensing, collaboration and acquisition), 2021 through August 2026. Values are as disclosed, so totals are a floor. Click a year to list its deals.

Show
Deals
China-linked vs non-China deals
Medians of the deals that disclosed each figure

How much weight loss is now the bar?

Best demonstrated obesity weight loss for leading incretin assets: the mean percent body-weight change at the highest studied dose, from pivotal readouts through August 2026. Timepoints differ by asset, so cross-trial comparison is our read, not head to head (except REDEFINE-4). Click a dot for the trial.

Estimand
InjectableOral

What reads out between August 2026 and the end of 2027?

Forward GLP-1 and incretin catalysts, dated by expected trial primary completion or expected regulatory decision. A ring marks a hard-outcome readout. Click a catalyst for the trial.

Show
Data readoutRegulatory or approvalHard outcome

Which GLP-1 combinations have actually matured?

Active programs grouped by target combination into mechanism families, by stage. Beside it, a separate set of drug-plus-drug co-administration regimens; the two sets are counted apart. Click a family or an approach to see what is inside.

Incretin (mature)Legacy GLP-1 coreNovel-partner frontier
20 key combination approaches
Drug-plus-drug co-administration regimens by partner class

Who is tackling muscle loss, and do the combinations work?

Muscle-preservation positioning scored per program from public materials, layered with Phase 2 body-composition readouts from the leading muscle-preserving combinations.

Positioning
Phase 2 combination proof
Click a trial for the arm-level data

Can oral GLP-1s scale against the injectables?

Route of administration across active programs with a stated route, the late-stage subset, and the split of oral programs by molecule type.

SubcutaneousOralOther

How many patients stay on GLP-1s, and why do they stop?

Discontinuation across the real-world, claims and trial studies in the report, most measured at six months, colored by each study's top reported reason. Beside it, the share of discontinuations by driver. Hover a study for its details.

Most patients discontinue within six months
Drivers of discontinuation
Share of discontinuations citing each driver

Why do GLP-1 programs fail, and is it different for the incumbents?

37 discontinued or deprioritized GLP-1 and metabolic programs, sorted into six failure modes and split by incumbent (Novo, Lilly) versus entrant. Click a failure mode to list its programs.

Incumbents (n = 9)Entrants (n = 28)
The commercial bar entrants must clear
Beyond the clinical profile

How does China feed the West's next GLP-1s?

The China fast-follower chain end to end: the Western catalysts, the copy wave, the license-backs and the capital behind them, 2018 to 2026. Click a step to see what sits behind it.

What do we expect next?

Explore the Data Behind the Report

The Excel behind this report (Deals, Weight Loss Benchmarks, Discontinued Programs, and China Fast-Followers) is free for Sleuth Intelligence Community members. Not a member yet? Join the community.